藥品參考
Ramucirumab
Ramucirumab is a medicine in the class oncology. It is used for colorectal cancer.
- 藥物類別: Oncology
- 用途: colorectal cancer
最後更新
僅供醫療專業人員參考。本頁為簡要摘要，並非醫療建議，亦不能取代官方仿單或臨床判斷。開立處方或調劑前請務必核實。
本頁的臨床內容僅提供英文版。
重點資訊
- 藥物類別
- Oncology
- ATC 代碼
- L01FX06
- 常見劑型
- 注射劑, 溶液
- 常見規格
- 10 mg/ml, 100 mg/10 ml, 500 mg/50 ml
- 已知交互作用
- 2 (中度: 2)
- 商品名
- 7
- 國家與市場
- 5
用途
作用方式
Vascular endothelial growth factor receptor 2 (VEGFR2) antagonist that specifically binds VEGF receptor 2 and blocks binding of VEGFR ligands, VEGF-A, VEGF-C, and VEGF-D. As a result, ramucirumab inhibits ligand-stimulated activation of VEGF2, thereby inhibiting ligand-induced proliferation, and migration of human endothelial cells.
成人常用劑量（仿單摘要）
Non-Small Cell Lung Cancer: Ramucirumab 10 mg/kg IV on Day 1, PLUS Docetaxel 75 mg/m2 IV on Day 1, Repeat cycle every 21 days, Continue until disease progression or unacceptable toxicity.
懷孕與哺乳
- 懷孕
- Unsafe Can cause fetal harm: it blocks VEGFR2, which the placenta and fetal blood vessels need (mice lacking VEGFR2 die as embryos); no human or animal reproduction studies. Check pregnancy status before starting; use effective contraception during treatment and for 3 months after the last dose.
- 哺乳
- Unsafe No human milk data. As a large antibody, milk levels are likely very low and poorly absorbed, but serious infant reactions are possible. Do not breastfeed during treatment and for 2 months after the last dose (US label; LactMed concurs with caution).
已通報的副作用
- Fatigue
- Diarrhea
- Asthenia
- Neutropenia
- Hypertension
- Epistaxis
哪些人需要特別留意
- Impaired wound healing can occur with antibodies inhibiting the VEGF or VEGFR pathway; VEGFR2 antagonist has the potential to adversely affect wound healing
- Withhold for 28 days prior to elective surgery; do not administer for at least 2 weeks following a major surgical procedure and until adequate wound healing
- May cause hypothyroidism; monitor thyroid function during treatment
請告知藥師或醫師您是否懷孕或哺乳、是否患有腎臟或肝臟疾病、是否有過敏，以及您正在使用的所有其他藥物或保健品。
重要交互作用 (2)
同類別的其他藥品
常見問題
What is Ramucirumab used for?
Ramucirumab is a medicine in the class oncology. It is used for Colorectal cancer, Gastric cancer, Hepatocellular carcinoma, Lung cancer.
What side effects have been reported with Ramucirumab?
Fatigue, Diarrhea, Asthenia, Neutropenia, Hypertension, Epistaxis.
Can Ramucirumab be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. Can cause fetal harm: it blocks VEGFR2, which the placenta and fetal blood vessels need (mice lacking VEGFR2 die as embryos); no human or animal reproduction studies. Check pregnancy status before starting; use effective contraception during treatment and for 3 months after the last dose. Breastfeeding: Unsafe. No human milk data. As a large antibody, milk levels are likely very low and poorly absorbed, but serious infant reactions are possible. Do not breastfeed during treatment and for 2 months after the last dose (US label; LactMed concurs with caution).
What does Ramucirumab interact with?
MediHelp lists 2 known interactions for Ramucirumab. Moderate: 2. The most serious include Efgartigimod / hyaluronidase sc, Efgartigimod alfa.
在 MediHelp App 中取得完整藥品專論、劑量資訊與交互作用檢查
在 MediHelp App 中開啟完整參考資料、檢查多種藥物間的交互作用，並使用劑量工具。
